Author: admin

LightsNearMe.com Launches Industry-Specific Directory to Help Lighting Professionals Improve SEO & Online Visibility

“Lighting Design and Landscape Lighting Professionals – Helping lighting contractors, designers, and consultants improve online visibility and strengthen local SEO”
LightsNearMe.com is a new niche directory built exclusively for lighting designers, landscape lighting contractors, lighting consultants, and specialty lighting companies. Businesses can claim and verify their listings to strengthen local SEO, improve online visibility, showcase services and social profiles, and help potential customers find trusted lighting professionals more easily.

Lights Near Me, a new niche business directory built exclusively for the lighting industry, is officially launching to help lighting professionals improve their online presence, increase business credibility, and strengthen search engine visibility.

Created specifically for lighting designers, landscape lighting contractors, lighting consultants, and specialty lighting companies, Lightsnearme.com provides a targeted platform where industry professionals can claim and verify their business lighting to improve discoverabiltiy across the web.

Unlike broad, overcrowded business directories, Lights Near Me focuses solely on the lighting industry, allowing businesses to showcase detailed company information, service areas, contact information, websites, social profiles, project images, and more, all within a categroy-specific environment designed to support SEO performance.

“Today’s consumers search online first, and businesses that appear consistently across trusted directoris have a stronger opportunity to be found,” said the founder of Lights Near Me. “Our goal is to give lighting professionals an affordable, industry-focused platform that helps support online visibility while building trust with potential customers.”

Businesses can claim their listings for just $20/month, with an optional annual business verification for $60/year, helping establish credibility and consumer condifence while enhancing online citation consistency.

For lighting business owners and SEO agencies looking to strengthen local search visibility, Lightsnearme.com offers an affordable way to expand digital footprint, improve business consistency online, and gain exposure within a highly targeted industry network.

To claim or verify a business listing, visit LightsNearMe.com

Media Contact
Company Name: Lights Near Me
Contact Person: Bryan Daniel
Email: Send Email
Country: United States
Website: www.lightsnearme.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LightsNearMe.com Launches Industry-Specific Directory to Help Lighting Professionals Improve SEO & Online Visibility

Essential Thrombocythemia Market is Expected to Witness Significant Growth by 2034 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

The market dynamics for Essential Thrombocythemia are anticipated to witness notable growth driven by the increasing prevalence of ET, growing awareness regarding myeloproliferative neoplasms, advancements in genetic mutation testing, and increasing focus on preventing thrombotic complications. Additionally, the development of emerging therapies such as BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), and others will further support the expansion of the ET treatment market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Essential Thrombocythemia (ET) Market Insights, Epidemiology, and Market Forecast 2034.” This comprehensive report provides an in-depth understanding of ET, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Essential Thrombocythemia (ET) Market

  • The market size for Essential Thrombocythemia in the 7MM is expected to increase significantly during the forecast period 2020–2034.

  • The United States accounted for the highest ET market size among the 7MM in 2024 compared to EU4 countries, the United Kingdom, and Japan.

  • According to a study conducted by Thompson et al., the estimated prevalence of ET was around 18 cases per 100,000 population annually.

  • In France, approximately 1–2.5 new cases per 100,000 inhabitants are reported annually, while the prevalence is nearly 1 case per 3,330 individuals.

  • According to Bloodwise, nearly 60% of ET patients harbor the JAK2 mutation, around 30% have CALR mutations, and approximately 5% possess MPL mutations.

  • Leading ET companies such as Merck, PharmaEssentia, Novartis, and pharma& are developing innovative therapies to improve treatment outcomes and reduce thrombotic complications associated with ET.

  • Promising ET pipeline therapies include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/essential-thrombocythemia-et-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Essential Thrombocythemia Market

Increasing Disease Prevalence and Improved Diagnosis:Rising awareness regarding myeloproliferative neoplasms, along with increasing adoption of genetic mutation testing for JAK2, CALR, and MPL mutations, is supporting earlier diagnosis and improved disease management.

Growing Focus on Prevention of Thrombotic Complications:The primary treatment objective in ET remains the prevention of thrombotic and hemorrhagic events, which are major causes of morbidity and mortality among ET patients.

Emergence of Novel Targeted Therapies:The growing development of targeted therapies including LSD1 inhibitors, interferons, and BET inhibitors is expected to improve long-term disease control and therapeutic outcomes in ET patients.

Essential Thrombocythemia Competitive Landscape

  • Several ET therapies in development include Bomedemstat (Merck), Ropeginterferon alfa-2b (PharmaEssentia), and Pelabresib (Novartis).

  • These therapies target diverse mechanisms such as LSD1 inhibition, interferon stimulation, and BET protein inhibition aimed at improving hematologic response, reducing thrombosis risk, and enhancing long-term disease management in ET patients.

Discover more about therapies set to grab major Essential Thrombocythemia market share @ Essential Thrombocythemia Treatment Landscape

Recent Developments in the Essential Thrombocythemia Market

  • In November 2025, Merck presented Phase III extension study data evaluating the safety of Bomedemstat in ET patients at the American Society of Hematology (ASH) Annual Meeting and Exposition.

  • In July 2025, pharma& announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for PEGASYS as a monotherapy treatment for adults with ET and polycythemia vera.

  • In November 2025, PharmaEssentia announced positive results from the pivotal Phase III SURPASS-ET clinical trial evaluating ropeginterferon alfa-2b.

  • In November 2025, PharmaEssentia also announced expectations for US FDA regulatory approval of ropeginterferon alfa-2b in 2026 following regulatory submission planned by the end of 2025.

What is Essential Thrombocythemia (ET)?

  • Essential Thrombocythemia is a chronic myeloproliferative neoplasm characterized by excessive production of platelets in the bone marrow. The disease is associated with an increased risk of thrombosis, hemorrhage, and transformation into myelofibrosis or acute leukemia.

  • ET is commonly associated with mutations in JAK2, CALR, and MPL genes. Diagnosis typically involves bone marrow biopsy, genetic testing, and evaluation of clinical risk factors.

  • Current treatment strategies focus on reducing platelet counts and preventing vascular complications using therapies such as aspirin, hydroxyurea, interferons, and anagrelide.

Essential Thrombocythemia Epidemiology Segmentation

The Essential Thrombocythemia epidemiology section provides insights into the historical and current ET patient pool and forecasted trends for the leading markets. The ET market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of ET

  • Symptom-specific Cases of ET

  • Gender-specific Cases of ET

  • Mutation-specific Cases of ET

  • Risk-specific Cases of ET

  • Age-specific Cases of ET

  • Total Treated Cases of ET

Scope of the Essential Thrombocythemia Market Report

  • Therapeutic Assessment: ET current marketed and emerging therapies

  • ET Market Dynamics: Key Market Forecast Assumptions and Market Outlook

  • Key Companies: Merck, PharmaEssentia, Novartis, pharma&, and others

  • Key Therapies: PEGASYS, BESREMi, Bomedemstat, Pelabresib, Hydroxyurea, Aspirin, Anagrelide, and others

  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, ET Market Access and Reimbursement

To know more about Essential Thrombocythemia companies working in the treatment market, visit @ Essential Thrombocythemia Clinical Trials and Therapeutic Assessment

Table of Contents

  1. Essential Thrombocythemia Market Report Introduction

  2. Executive Summary for ET

  3. SWOT Analysis of ET

  4. ET Patient Share (%) Overview at a Glance

  5. ET Market Overview at a Glance

  6. ET Background and Overview

  7. ET Epidemiology and Patient Population

  8. Country-Specific Patient Population of ET

  9. ET Current Treatment and Medical Practices

  10. ET Unmet Needs

  11. ET Emerging Therapies

  12. ET Market Outlook

  13. Country-Wise ET Market Analysis (2020–2034)

  14. ET Market Access and Reimbursement of Therapies

  15. ET Market Drivers

  16. ET Market Barriers

  17. ET Appendix

  18. ET Report Methodology

  19. DelveInsight Capabilities

  20. Disclaimer

  21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Essential Thrombocythemia Market is Expected to Witness Significant Growth by 2034 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

Xerostomia Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

The market dynamics for Xerostomia are anticipated to witness notable growth driven by the increasing prevalence of xerostomia associated with aging populations, rising polypharmacy use, increasing cases of Sjögren’s syndrome, growing head and neck cancer survivorship, and improved awareness regarding oral health management. Additionally, the development of emerging therapies such as LBS-020, AAV-hAQP1, and others will further support the expansion of the xerostomia treatment market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Xerostomia Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Xerostomia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Xerostomia Market

  • The market size for Xerostomia in the leading markets is expected to increase significantly during the forecast period 2022–2036.

  • The United States accounted for the highest Xerostomia market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.

  • According to Huang et al. (2025), a systematic review and meta-analysis involving 2,486 patients with type 2 diabetes across 16 countries reported an overall xerostomia prevalence of 42.5%, highlighting diabetes as a major contributor to xerostomia burden globally.

  • According to Rughwani et al. (2025), a Swedish study involving 1.39 million adults reported a diagnosed xerostomia prevalence of 0.23%, with nearly 73.1% of cases occurring in women and 41.5% in individuals aged above 71 years.

  • According to the European Association of Oral Medicine (2022), xerostomia occurs in approximately 17–39% of individuals aged 65 years or older and is more frequently observed in women than men.

  • Leading Xerostomia companies such as Lubris BioPharma, MeiraGTx, and others are developing innovative therapies aimed at improving salivary gland function and long-term disease management.

  • Promising Xerostomia pipeline therapies include LBS-020 and AAV-hAQP1, among others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/xerostomia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Xerostomia Market

Increasing Disease Burden and Aging Population:The growing prevalence of xerostomia among elderly populations, patients with chronic diseases, and individuals undergoing head and neck radiation therapy is significantly contributing to market growth.

Rising Demand for Effective Symptomatic Therapies:Current therapies such as pilocarpine and cevimeline continue to remain widely used for improving salivary secretion and reducing oral discomfort associated with xerostomia.

Growing Focus on Regenerative and Gene-based Therapies:Pharmaceutical companies are increasingly focusing on regenerative salivary gland therapies, gene therapies, stem cell approaches, and radioprotective agents that may offer disease-modifying benefits beyond temporary symptom relief.

Xerostomia Competitive Landscape

  • Several Xerostomia therapies in development include LBS-020 (Lubris BioPharma) and AAV-hAQP1 (MeiraGTx).

  • These therapies target diverse mechanisms such as recombinant lubricin-based oral lubrication and aquaporin-1 gene therapy designed to restore salivary gland function and improve saliva production in radiation-induced xerostomia patients.

Discover more about therapies set to grab major Xerostomia market share @ Xerostomia Treatment Landscape

Recent Developments in the Xerostomia Market

  • In April 2026, MeiraGTx announced presentation of 3-year data from the Phase I AQUAx clinical study evaluating AAV-hAQP1 for Grade 2/3 radiation-induced xerostomia.

  • AAV-hAQP1 is currently being evaluated in Phase III clinical trials for radiation-induced xerostomia.

  • Lubris BioPharma continues to advance LBS-020 as a novel recombinant lubricin-based therapy designed to improve oral lubrication and provide longer-lasting symptomatic relief compared to traditional saliva substitutes.

  • Researchers in the United States are also developing reusable hydrogel reservoir technologies capable of gradually releasing artificial saliva in the oral cavity, potentially providing sustained symptom relief for xerostomia patients.

What is Xerostomia?

Xerostomia is defined as the subjective sensation or complaint of oral dryness. It may result from reduced salivary secretion due to salivary gland dysfunction or may occur despite normal salivary gland activity.

The condition is commonly associated with medications, autoimmune diseases, endocrine disorders, head and neck radiation therapy, chemotherapy, and lifestyle factors. Patients often experience difficulty swallowing, speaking, chewing, altered taste, oral infections, and dental complications that significantly affect quality of life.

Currently approved systemic therapies for xerostomia include pilocarpine (SALAGEN) and cevimeline (EVOXAC), while topical therapies and saliva substitutes remain important supportive treatment options.

Xerostomia Epidemiology Segmentation

The Xerostomia epidemiology section provides insights into the historical and current Xerostomia patient pool and forecasted trends for the leading markets. The Xerostomia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Xerostomia

  • Treatment Eligible Cases of Xerostomia

  • Age-specific Diagnosed Prevalent Cases of Xerostomia

  • Gender-specific Diagnosed Prevalent Cases of Xerostomia

Scope of the Xerostomia Market Report

  • Therapeutic Assessment: Xerostomia current marketed and emerging therapies

  • Xerostomia Market Dynamics: Key Market Forecast Assumptions and Market Outlook

  • Key Companies: Lubris BioPharma, MeiraGTx, and others

  • Key Therapies: LBS-020, AAV-hAQP1, Pilocarpine (SALAGEN), Cevimeline (EVOXAC), and others

  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Xerostomia Market Access and Reimbursement

To know more about Xerostomia companies working in the treatment market, visit @ Xerostomia Clinical Trials and Therapeutic Assessment

Table of Contents

  1. Xerostomia Market Report Introduction

  2. Executive Summary for Xerostomia

  3. SWOT Analysis of Xerostomia

  4. Xerostomia Patient Share (%) Overview at a Glance

  5. Xerostomia Market Overview at a Glance

  6. Xerostomia Background and Overview

  7. Xerostomia Epidemiology and Patient Population

  8. Country-Specific Patient Population of Xerostomia

  9. Xerostomia Current Treatment and Medical Practices

  10. Xerostomia Unmet Needs

  11. Xerostomia Emerging Therapies

  12. Xerostomia Market Outlook

  13. Country-Wise Xerostomia Market Analysis (2022–2036)

  14. Xerostomia Market Access and Reimbursement of Therapies

  15. Xerostomia Market Drivers

  16. Xerostomia Market Barriers

  17. Xerostomia Appendix

  18. Xerostomia Report Methodology

  19. DelveInsight Capabilities

  20. Disclaimer

  21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Xerostomia Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

Basal Cell Carcinoma Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

The market dynamics for Basal Cell Carcinoma (BCC) are anticipated to witness notable growth driven by the increasing incidence of BCC, heightened UV exposure, aging population, growing awareness regarding early diagnosis, and the launch of emerging therapies. Additionally, the development of promising therapies such as LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), STP705 (Sirnaomics), and others will further support the market expansion.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Basal Cell Carcinoma (BCC) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Basal Cell Carcinoma, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Basal Cell Carcinoma Market

  • The market size for Basal Cell Carcinoma in the leading markets is expected to increase significantly during the forecast period 2022–2036.

  • The United States accounted for the highest Basal Cell Carcinoma market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.

  • According to the Skin Cancer Foundation (2023), BCC is the most common form of skin cancer, with an estimated 3.6 million cases diagnosed annually in the United States.

  • According to the American Cancer Society (2023), approximately 5.4 million basal and squamous cell skin cancers are diagnosed each year in about 3.3 million persons in the US, with nearly 80% of those cases being BCCs.

  • A 2025 JAMA Dermatology study based on Global Burden of Disease (GBD) 2021 data estimated approximately 2.8 million incident BCC cases globally in 2021, making it the most common skin cancer worldwide.

  • According to Roky et al. (2025), approximately 700,000 new BCC cases are diagnosed annually in Europe, with incidence rates continuing to increase by nearly 5.5% per year.

  • Leading BCC companies such as Lytix Biopharma, Verrica Pharmaceuticals, Sirnaomics, Stamford Pharmaceuticals, Philogen, Sun Pharmaceutical, Medivir/Biossil, and others are developing novel BCC treatment approaches to improve patient outcomes.

  • Promising Basal Cell Carcinoma pipeline therapies include LTX-315/VP-315, STP705, SP-002, Remetinostat, NIDLEGY, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Basal Cell Carcinoma Market

Increasing Incidence of BCC and UV Exposure:Rising exposure to ultraviolet (UV) radiation, lifestyle changes, and an aging population are major contributors to the increasing incidence of BCC globally. Growing awareness and improved diagnosis rates are further increasing treatment demand.

Growing Adoption of Targeted and Immunotherapy Approaches:Targeted Hedgehog pathway inhibitors (HHPIs) such as vismodegib and sonidegib, along with immunotherapies like cemiplimab, are significantly improving outcomes in advanced and locally advanced BCC patients.

Advancements in Non-surgical and Topical Therapies:The increasing use of topical therapies, photodynamic therapy, and emerging non-surgical treatment options is expanding the therapeutic landscape for patients unsuitable for surgery.

Basal Cell Carcinoma Competitive Landscape

  • Several BCC therapies in development include LTX-315/VP-315 (Lytix Biopharma/Verrica Pharmaceuticals), STP705 (Sirnaomics), SP-002 (Stamford Pharmaceuticals), Remetinostat (Medivir/Biossil), and NIDLEGY (Philogen/Sun Pharmaceutical).

  • These therapies target diverse mechanisms such as oncolytic peptide immunotherapy, TGF-ß1/COX-2 inhibition, adenovirus-mediated interferon-gamma delivery, and histone deacetylase inhibition to improve treatment efficacy and provide alternatives to invasive surgical approaches.

Discover more about therapies set to grab major Basal Cell Carcinoma market share @ Basal Cell Carcinoma Treatment Landscape

Recent Developments in the Basal Cell Carcinoma Market

  • In April 2026, Verrica Pharmaceuticals announced that a late-breaking abstract on VP-315 (ruxotemitide) was accepted for presentation at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, highlighting Phase II exploratory data supporting its immunologic activity and non-surgical treatment potential.

  • In March 2025, Verrica Pharmaceuticals received positive FDA feedback from the end-of-Phase II meeting supporting an efficient Phase III program and registration pathway for VP-315 in BCC.

  • In January 2025, Stamford Pharmaceuticals announced positive Phase IIa trial results for SP-002 in combination with vismodegib in subjects with multiple BCCs.

  • Stamford Pharmaceuticals also announced plans to initiate Phase III development of SP-002 for BCC during 2H 2025/1H 2026.

  • Sirnaomics reported encouraging Phase II clinical study results for STP705 demonstrating strong efficacy without significant drug-related adverse effects in BCC treatment.

What is Basal Cell Carcinoma (BCC)?

Basal Cell Carcinoma (BCC), previously known as basal cell epithelioma, is the most common form of skin cancer and among the most frequently diagnosed cancers worldwide. BCC is generally a slow-growing and locally invasive tumor that rarely metastasizes.

BCC commonly develops on sun-exposed areas of the skin and is strongly associated with cumulative ultraviolet radiation exposure. Common treatment approaches include surgical excision, Mohs micrographic surgery, topical therapies, radiation therapy, cryotherapy, photodynamic therapy, and systemic therapies for advanced disease.

FDA-approved therapies for advanced BCC include cemiplimab (LIBTAYO), vismodegib (ERIVEDGE), and sonidegib (ODOMZO).

Basal Cell Carcinoma Epidemiology Segmentation

The Basal Cell Carcinoma epidemiology section provides insights into the historical and current BCC patient pool and forecasted trends for the leading markets. The Basal Cell Carcinoma market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Non-Melanoma Skin Cancer

  • Total Incident Cases of BCC

  • Subtype-specific Incident Cases of BCC

  • Stage-specific Incident Cases of BCC

  • Line-wise Treated Cases of BCC

Scope of the Basal Cell Carcinoma Market Report

  • Therapeutic Assessment: Basal Cell Carcinoma current marketed and emerging therapies

  • Basal Cell Carcinoma Market Dynamics: Key Market Forecast Assumptions and Market Outlook

  • Key Companies: Lytix Biopharma, Verrica Pharmaceuticals, Sirnaomics, Stamford Pharmaceuticals, Philogen, Sun Pharmaceutical, Medivir/Biossil, and others

  • Key Therapies: LTX-315/VP-315, STP705, SP-002, Remetinostat, NIDLEGY, LIBTAYO, ODOMZO, ERIVEDGE, and others

  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Basal Cell Carcinoma Market Access and Reimbursement

To know more about Basal Cell Carcinoma companies working in the treatment market, visit @ Basal Cell Carcinoma Clinical Trials and Therapeutic Assessment

Table of Contents

  1. Basal Cell Carcinoma Market Report Introduction

  2. Executive Summary for Basal Cell Carcinoma

  3. SWOT Analysis of Basal Cell Carcinoma

  4. Basal Cell Carcinoma Patient Share (%) Overview at a Glance

  5. Basal Cell Carcinoma Market Overview at a Glance

  6. Basal Cell Carcinoma Background and Overview

  7. Basal Cell Carcinoma Epidemiology and Patient Population

  8. Country-Specific Patient Population of Basal Cell Carcinoma

  9. Basal Cell Carcinoma Current Treatment and Medical Practices

  10. Basal Cell Carcinoma Unmet Needs

  11. Basal Cell Carcinoma Emerging Therapies

  12. Basal Cell Carcinoma Market Outlook

  13. Country-Wise Basal Cell Carcinoma Market Analysis (2022–2036)

  14. Basal Cell Carcinoma Market Access and Reimbursement of Therapies

  15. Basal Cell Carcinoma Market Drivers

  16. Basal Cell Carcinoma Market Barriers

  17. Basal Cell Carcinoma Appendix

  18. Basal Cell Carcinoma Report Methodology

  19. DelveInsight Capabilities

  20. Disclaimer

  21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Basal Cell Carcinoma Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

Food Allergy Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Food Allergy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Food Allergy pipeline landscape. It covers the Food Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Food Allergy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Food Allergy Pipeline? @ https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight

Key Takeaways from the Food Allergy Pipeline Report

  • On May 19, 2026- Regeneron Pharmaceuticals initiated a study is researching an experimental drug called dupilumab (called “study drug”). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.
  • On May 11, 2026- ALK-Abelló A/S conducted a phase I/II clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy. The trial is conducted in 3 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents; part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children; part 3 will evaluate the efficacy of 2 maintenance doses of the SLIT-tablet primarily in adolescents and children; a small number of adults may also be included.
  • On May 04, 2026- RAPT Therapeutics Inc. announced a Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks.
  • DelveInsight’s Food Allergy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Food Allergy treatment.
  • The leading Food Allergy Companies, such as DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.
  • Promising Food Allergy Therapies such as Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib and others.

Want to know which companies are leading innovation in Food Allergy? @ Food Allergy Clinical Trials Assessment

The Food Allergy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Food Allergy Pipeline Report also highlights the unmet needs with respect to the Food Allergy.

Food Allergy Overview

Food allergies are adverse health effects resulting from a specific immune response that occurs reproducibly on exposure to a given food. These immune responses can range from mild to severe, potentially affecting the skin, gastrointestinal tract, respiratory, and cardiovascular systems. Food allergies are distinct from food intolerances, which do not involve the immune system and are generally less severe. The prevalence of food allergies has been rising, especially in developed countries, with an estimated 5-8% of children and 1-2% of adults affected worldwide.

Food Allergy Emerging Drugs Profile

  • Viaskin Peanut: DBV Technologies

Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The drug is currently being investigated in the Registration stage of development for the treatment of peanut allergy.

  • PVX-108: Aravax

PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is designed to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favorable safety profile for treatment of peanut allergic patients, including those with severe allergy. The drug is currently being investigated in the Phase II stage of development for the treatment of peanut allergy.

  • INT301: Intrommune Therapeutics

INT301 is an investigational oral mucosal immunotherapy (OMIT) product developed by Intrommune Therapeutics for the treatment of peanut allergy. It is a toothpaste-based formulation designed for daily use, delivering allergen proteins directly to the immune system via the oral mucosa to induce desensitization. Unlike traditional oral immunotherapy (OIT), INT301 aims to reduce allergic reactions with improved safety and convenience. The product is currently in clinical development. The drug is currently being investigated in the Phase I stage of development for the treatment of peanut allergy.

If you’re tracking ongoing Food Allergy Clinical trials, this press release is a must-read @ Food Allergy Treatment Drugs

The Food Allergy Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment.
  • Food Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market.

Food Allergy Companies

DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.

Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Food Allergy Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

From emerging drug candidates to competitive intelligence, the Food Allergy Pipeline Report covers it all @ Food Allergy Market Drivers and Barriers, and Future Perspectives

Scope of the Food Allergy Pipeline Report

  • Coverage- Global
  • Food Allergy Companies- DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune and others.
  • Food Allergy Therapies- Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib and others.
  • Food Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Food Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Food Allergy Treatment landscape in this detailed analysis @ Food Allergy Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Food Allergy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Food Allergy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Viaskin Peanut: DBV Technologies
  9. Mid Stage Products (Phase II)
  10. PVX-108: Aravax
  11. Early Stage Products (Phase I)
  12. INT301: Intrommune Therapeutics
  13. Drug profiles in the detailed report…..
  14. Preclinical and Discovery Stage Products
  15. Drug Name: Company Name
  16. Inactive Products
  17. Food Allergy Key Companies
  18. Food Allergy Key Products
  19. Food Allergy- Unmet Needs
  20. Food Allergy- Market Drivers and Barriers
  21. Food Allergy- Future Perspectives and Conclusion
  22. Food Allergy Analyst Views
  23. Food Allergy Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/food-allergy-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/food-allergy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Allergy Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Epidermolysis Bullosa Treatment Pipeline Shows Strong Momentum as 18+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Epidermolysis Bullosa Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 22+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight

Key Takeaways from the Epidermolysis Bullosa Pipeline Report

  • On May 20, 2026, Xinnate AB initiated a Phase 2 study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.
  • DelveInsight’s Epidermolysis Bullosa pipeline report depicts a robust space with 18+ active players working to develop 22+ pipeline therapies for Epidermolysis Bullosa treatment.
  • The leading Epidermolysis Bullosa Companies such as BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others.
  • Promising Epidermolysis Bullosa Pipeline Therapies such as diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.

Learn how leading Epidermolysis Bullosa Companies are positioning themselves for success in the evolving pharmaceutical market @ Epidermolysis Bullosa Clinical Trials Assessment

Epidermolysis Bullosa Overview

Epidermolysis Bullosa refers to a group of rare inherited skin disorders characterized by extreme skin fragility, leading to recurrent blistering, erosions, and ulcers even after minor mechanical trauma. These conditions arise from genetic defects affecting proteins at the dermo-epidermal junction, resulting in impaired skin integrity. EB presents with a wide spectrum of severity, with some forms associated with chronic infections, scarring, deformities, and an elevated risk of aggressive skin cancers. In addition to cutaneous symptoms, patients may experience systemic complications that contribute to significant morbidity and early mortality.

Epidermolysis Bullosa Emerging Drugs

  • BM-3103: BioMendics

TolaSure (BM-3103) is a topical therapeutic candidate being developed for the treatment of Epidermolysis Bullosa, a rare genetic skin disorder characterized by fragile skin and chronic blistering. The formulation is designed to enhance wound healing, reduce inflammation, and strengthen skin integrity at affected sites. By targeting local tissue repair mechanisms, it aims to accelerate re-epithelialization and minimize infection risk. TolaSure offers a non-invasive approach with the potential to improve quality of life in patients with this debilitating condition. BM-3103 is currently in Phase II stage of its development for the treatment of of Epidermolysis Bullosa.

  • AGLE-102: Aegle Therapeutics

AGLE-102 is an investigational exosome-based therapy being developed for the treatment of Epidermolysis Bullosa. Derived from mesenchymal stem cells, it delivers bioactive molecules that promote tissue repair, reduce inflammation, and support skin regeneration. The therapy aims to accelerate wound closure and improve skin integrity in affected patients. AGLE-102 represents a novel, cell-free regenerative approach with potential to address the underlying pathology of this debilitating condition. It is currently being evaluated in a Phase I/II clinical trial for the treatment of Epidermolysis Bullosa.

Don’t miss this opportunity to stay informed—download now! @ Epidermolysis Bullosa Treatment Drugs

The Epidermolysis Bullosa Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
  • Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.

Epidermolysis Bullosa Companies

BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others

Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Epidermolysis Bullosa Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download our report for a deep dive into the next generation of therapeutics! @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives

Scope of the Epidermolysis Bullosa Pipeline Report

  • Coverage- Global
  • Epidermolysis Bullosa Companies- BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others.
  • Epidermolysis Bullosa Pipeline Therapies- diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
  • Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download now to stay at the forefront of pharmaceutical innovation!” @ Epidermolysis Bullosa Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Epidermolysis Bullosa: Overview
  4. Pipeline Therapeutics
  5. Therapeutics Assessment
  6. Epidermolysis Bullosa– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase II)
  9. BM-3103: BioMendics
  10. Early Stage Products (Phase I/II)
  11. AGLE-102: Aegle Therapeutics
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. Epidermolysis Bullosa Key Companies
  15. Epidermolysis Bullosa Key Products
  16. Epidermolysis Bullosa- Unmet Needs
  17. Epidermolysis Bullosa- Market Drivers and Barriers
  18. Epidermolysis Bullosa- Future Perspectives and Conclusion
  19. Epidermolysis Bullosa Analyst Views
  20. Epidermolysis Bullosa Key Companies
  21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epidermolysis Bullosa Treatment Pipeline Shows Strong Momentum as 18+ Pharma Companies in the Race | DelveInsight

Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Expands as 22+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Cutaneous T-cell lymphoma Pipeline Insight 2026” report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape @ https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report

  • On May 05, 2026, the University of Michigan Rogel Cancer Center initiated a phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter.
  • On May 01, 2026, Bristol-Myers Squibb conducted a phase 1/2 study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
  • DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 22+ active players working to develop 25+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
  • The leading Cutaneous T-Cell Lymphoma Companies such as Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others.
  • Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.

Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

The Cutaneous T-Cell Lymphoma Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Cutaneous T-Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Cutaneous T-Cell Lymphoma.

Cutaneous T-Cell Lymphoma Overview

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin. It originates from T-cells, a type of white blood cell that plays a critical role in the immune system. In CTCL, these T-cells become malignant and migrate to the skin, where they cause patches, plaques, or tumors. The disease typically progresses slowly, and early stages may resemble common skin conditions such as eczema or psoriasis, making diagnosis challenging. The two most common subtypes of CTCL are mycosis fungoides and Sézary syndrome, though there are several other, less common forms.

Cutaneous T-Cell Lymphoma Emerging Drugs

Lacutamab: Innate Pharma

Lacutamab (IPH4102) is a first-in-class humanized cytotoxicity-inducing antibody targeting KIR3DL2, currently being evaluated in Phase II clinical trials for cutaneous T-cell lymphoma (CTCL), a rare orphan malignancy. KIR3DL2 is an inhibitory receptor of the KIR family expressed in around 65% of CTCL patients across all subtypes, with expression rising up to 90% in aggressive forms such as Sézary syndrome. The drug remains in Phase II development for CTCL.

KK2223: Kyowa Kirin, Inc.

KK2223 is a first-in-human investigational therapy being evaluated in Phase I clinical trials for relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and aggressive T-cell malignancy. The study is designed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamic profile in CTCL patients, including Sézary syndrome and mycosis fungoides. It is administered as an intravenous infusion under a dose-escalation and backfill design to determine the maximum tolerated dose. The trial also explores preliminary anti-tumor activity and biomarker responses in advanced T-cell lymphoma.

ONO-4685: Ono Pharmaceuticals

ONO-4685 is an investigational anti-PD-1/CD3 bispecific antibody being developed by Ono Pharmaceutical for relapsed or refractory T-cell lymphomas, including Cutaneous T-cell Lymphoma (CTCL). The therapy is designed to bind PD-1 on malignant T cells and CD3 on T cells, thereby redirecting and activating T-cell–mediated anti-tumor activity against lymphoma cells. ONO-4685 is being evaluated in a Phase I clinical trial as a monotherapy in patients with relapsed/refractory CTCL subtypes such as mycosis fungoides (MF) and Sézary syndrome (SS), with the study assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.

Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline @ Cutaneous T-Cell Lymphoma Unmet Needs

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
  • Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

Cutaneous T-Cell Lymphoma Companies

Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others.

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T-Cell Lymphoma Pipeline Report

  • Coverage- Global
  • Cutaneous T-Cell Lymphoma Companies- Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others.
  • Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
  • Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Cutaneous T-Cell Lymphoma (CTCL): Overview

4. Pipeline Theraeutics

5. Therapeutics Assessment

6. Cutaneous T-Cell Lymphoma (CTCL) – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Cutaneous T-Cell Lymphoma Key Companies

13. Cutaneous T-Cell Lymphoma Key Products

14. Cutaneous T-Cell Lymphoma Unmet Needs

15. Cutaneous T-Cell Lymphoma Market Drivers and Barriers

16. Cutaneous T-Cell Lymphoma Future Perspectives and Conclusion

17. Cutaneous T-Cell Lymphoma Analyst Views

18. Cutaneous T-Cell Lymphoma Key Companies

19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Expands as 22+ Companies Driving Innovation in the Therapeutics | DelveInsight

Endometrial Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Endometrial Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, Endometrial Cancer route of administration, and Endometrial Cancer molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Endometrial Cancer Treatment Landscape @ https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight

Key Takeaways from the Endometrial Cancer Pipeline Report

  • On May 28, 2026- Daiichi Sankyo conducted a phase 3 study to evaluate the efficacy and safety of T-DXd versus SoC chemotherapy with or without radiotherapy as adjuvant treatment in participants with HER2-expressing (IHC 3+/2+) endometrial cancer. Participants will be randomized 1:1 to either T-DXd or SoC chemotherapy. The primary objective will assess disease-free survival as assessed radiographically by BICR or by histopathologic confirmation of disease recurrence per local assessment.
  • On May 22, 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
  • On May 20, 2026- AstraZeneca initiated a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician’s choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
  • On May 20, 2026- BioNTech SE announced a phase III study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample.
  • DelveInsight’s Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Endometrial Cancer treatment.
  • The leading Endometrial Cancer Companies such as Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
  • Promising Endometrial Cancer Pipeline Therapies such as Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Endometrial Cancer Clinical Trials Assessment

Endometrial Cancer Overview

Endometrial cancer, originating from the inner lining of the uterus (endometrium), stands as the most prevalent gynecologic malignancy in developed nations, with its incidence on the rise. This increase is attributed to factors such as aging populations and escalating obesity rates. The majority of cases are diagnosed in postmenopausal women, with abnormal uterine bleeding serving as the most common presenting symptom. Early detection is common due to this symptom, leading to diagnoses at initial stages where treatment outcomes are more favorable.

Endometrial Cancer Emerging Drugs Profile

  • Selinexor: Karyopharm Therapeutics

Selinexor (XPOVIO) is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. The drug is being explored as a maintenance therapy for patients with advanced or recurrent endometrial cancer, particularly those with TP53 wild-type tumors. This approach is based on findings from the Phase III SIENDO study, which has shown promising results in improving progression-free survival (PFS) for this specific patient population. Currently it is being investigated in Phase III stage of development for the treatment of patients with Endometrial Cancer.

  • Abemaciclib: Eli Lilly and Company

Abemaciclib, developed by Eli Lilly, is showing promising clinical activity in combination with hormonal therapies for recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a phase 2 trial, abemaciclib plus hormonal therapy achieved a clinical benefit rate of 67% in EEC patients, with partial and complete responses observed and a median progression-free survival (PFS) around 6.1 months. Another study combining abemaciclib with letrozole demonstrated a 30% objective response rate and a median PFS of 9.1 months, with durable tumor shrinkage or stabilization in 75% of patients. Adding metformin to this combination further improved outcomes, inducing deeper and more durable responses by targeting multiple cancer pathways including estrogen receptor, CDK4/6, and PI3K. These findings support abemaciclib plus hormonal therapy as a promising treatment approach for recurrent ER-positive endometrial cancer, with ongoing trials confirming safety and efficacy.

  • NP137: NETRIS Pharma

NP137 is a humanized monoclonal antibody (IgG1) targeting netrin-1, a protein overexpressed in a large proportion of human cancers and associated with disease severity and resistance to therapy. By blocking netrin-1, NP137 is designed to restore apoptosis and reverse epithelial-to-mesenchymal transition (EMT), addressing critical mechanisms of resistance that limit the effectiveness of immune checkpoint inhibitors. Preclinical and early clinical studies have shown that NP137 has anti-cancer effects both as a monotherapy and in combination with chemotherapy or immunotherapy, with a favorable safety profile. According to the company’s pipeline the drug is in the Phase II stage of development for the treatment of patients with Endometrial Cancer.

  • CT-0508: Carisma Therapeutics

CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase I multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers are not eligible for treatment with currently available HER2-targeted therapies or who do not respond to treatment. The trial is enrolling participants who have tumors of any anatomical origin, but with the commonality of overexpressing the HER2 receptor on the cell surface, which is the target for our CAR-M. The Phase 1 clinical trial is first-of-its-kind, marking the first time that genetically engineered macrophages are being studied in humans. The trial continues to enroll patients at seven clinical sites in the U.S., including (i) the University of Pennsylvania Abramson Cancer Center, (ii) the University of North Carolina Lineberger Comprehensive Cancer Center, (iii) the City of Hope National Medical Center, (iv) the MD Anderson Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi) Oregon Health & Science University and (vii) Fred Hutchinson Cancer Center.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Endometrial Cancer Unmet Needs

The Endometrial Cancer Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Endometrial Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometrial Cancer Treatment.
  • Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometrial Cancer market

Endometrial Cancer Companies

Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular

Endometrial Cancer Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies

See the latest progress in drug development and clinical research @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Endometrial Cancer Pipeline Report

  • Coverage- Global
  • Endometrial Cancer Companies- Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
  • Endometrial Cancer Pipeline Therapies- Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.
  • Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Endometrial Cancer Pipeline Analysis Today! @ Endometrial Cancer Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Endometrial Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Endometrial Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Selinexor: Karyopharm Therapeutics
  9. Mid Stage Products (Phase II)
  10. Abemaciclib: Eli Lilly and Company
  11. Early Stage Products (Phase I/II)
  12. CT-0508: Carisma Therapeutics
  13. Preclinical and Discovery Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Endometrial Cancer Key Companies
  17. Endometrial Cancer Key Products
  18. Endometrial Cancer – Unmet Needs
  19. Endometrial Cancer – Market Drivers and Barriers
  20. Endometrial Cancer – Future Perspectives and Conclusion
  21. Endometrial Cancer Analyst Views
  22. Endometrial Cancer Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endometrial Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight

Key Takeaways from the Pancreatic Cancer Pipeline Report

  • On May 28, 2026- Shandong Suncadia Medicine Co., Ltd. initiated a phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.
  • On May 16, 2026- Daiichi Sankyo conducted a Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic cancer of the pancreas that has not been previously treated or that has not responded to previous chemotherapy.
  • DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for Pancreatic Cancer treatment.
  • The leading Pancreatic Cancer Companies such as Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others
  • Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer @ Pancreatic Cancer Treatment Drugs

Pancreatic cancer Overview

Pancreatic cancer is a malignant neoplasm that arises primarily from the ductal epithelial cells of the pancreas, most commonly presenting as pancreatic ductal adenocarcinoma. It is considered one of the most aggressive and lethal cancers, ranking among the leading causes of cancer-related mortality worldwide. The disease is characterized by poor prognosis, with reported 5-year survival rates generally ranging between 5% and 15%, reflecting its highly aggressive nature and late detection. Histologically, the majority of cases are adenocarcinomas, with tumors most frequently originating in the head of the pancreas, although they can also arise in the body and tail.

Pancreatic cancer Emerging Drugs

  • TQB2868: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

TQB2868 injection is a PD-1/TGF-β bifunctional fusion protein independently developed by Chia Tai Tianqing Pharmaceutical Group. It can block the PD-1/PD-L1 pathway and neutralize TGF-β in the tumor microenvironment, exhibiting dual effects of immune checkpoint inhibition and tumor microenvironment remodeling. The combined inhibition of PD-1 and TGF-β signaling can lead to a more effective anti-tumor immune response than inhibition of either pathway alone, thereby improving clinical benefits in anti-tumor treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of pancreatic cancer.

  • Trabedersen (OT-101): Oncotelic Inc./ Autotelic Bio Inc.

Trabedersen, also referred as OT-101 is a novel antisense oligodeoxynucleotide (ODN). It is a synthetic 18-mer phosphorothioate oligodeoxynucleotide (S-ODN) complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. Cancers overexpress TGF-β, which suppresses host innate immune response to the cancers. Treatment with OT-101 lifts the TGF-β cloaking effect and allows innate or therapeutic immunity to attack and eliminate the cancers. The drug has showed favorable safety and long-term disease control in over half of the treated patients in PDAC. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of pancreatic cancer.

  • Antroquinonol: Golden Biotechnology Corp.

Antroquinonol is a small molecule NCE with demonstrated activities both in-vivo and in-vitro against a number of malignancies, infectious diseases and neuro-degenerative diseases. Antroquinonol inhibited Ras and Ras-related GTP-binding protein activation through inhibition of protein isoprenyl transferase activity, leading to activation of autophagy and associated mode of cell death in cancer cells. Additionally, it can be taken orally, providing a convenient treatment option for patients. Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

  • Nadunolimab: Cantargia AB

Nadunolimab (CAN04) is an Anti-IL1RAP antibody for treatment of various cancer types. Nadunolimab binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. Nadunolimab blocks the signaling of interleukin-1, alpha and beta, thereby limiting tumor development as well as working synergistically with chemotherapy and adding functionality through Antibody-Dependent Cellular Cytotoxicity (ADCC). In June 2025, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to nadunolimab for for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) with high expression levels of IL1RAP in combination with gemcitabine and nab-paclitaxel. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of pancreatic cancer.

  • MT-601: Marker Therapeutics, Inc.

MT-601 is a promising Multi-Tumor Associated Antigen (multiTAA)-specific T cell therapy developed by Marker Therapeutics for treating advanced or metastatic pancreatic cancer. It is a non-genetically modified therapy that targets six antigens ommonly expressed in pancreatic tumors. Unlike CAR-T therapy, MT-601 is a non-genetically modified T cell product. It targets multiple tumor-associated antigens, which may reduce the risk of immune evasion by the tumor. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of pancreatic cancer.

  • fb-PMT: NanoPharmaceuticals

Fb-PMT (NP751) is a novel, potent thyrointegrin antagonist that has shown high effectiveness in preclinical studies for pancreatic cancer, reducing tumor weight and viability by over 90% in mice Fb-PMT works by targeting the thyrointegrin receptor, which is overexpressed on the surface of pancreatic cancer cells and dividing blood vessel cells, inducing anti-angiogenic and anticancer effects. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of pancreatic cancer.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline @ New Pancreatic Cancer Drugs

The Pancreatic Cancer Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
  • Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Pancreatic Cancer Companies

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others.

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Pancreatic Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Pancreatic Cancer Companies- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Oncotelic Inc., Golden Biotechnology Corp., Cantargia AB, Marker Therapeutics, Inc., NanoPharmaceuticals, Innovent Biologics/Takeda, Verastem, Inc., Autotelic Bio Inc., Oncolytics Biotech, Agenus Inc., ONO PHARMACEUTICAL CO., LTD., Merck Sharp & Dohme LLC., Akeso Biopharma Co., Ltd., ImmunityBio, Inc., NETRIS Pharma, Merck & Co., Inc., Nihon Medi-Physics Co., Ltd., FutureGen Biopharmaceutical (Beijing) Co., Ltd., Can-Fite Biopharma, and InxMed and others
  • Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
  • Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Pancreatic Cancer drug development? @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. CT041: CARsgen Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. DK210: DEKA Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Cancer Key Companies
  21. Pancreatic Cancer Key Products
  22. Pancreatic Cancer- Unmet Needs
  23. Pancreatic Cancer- Market Drivers and Barriers
  24. Pancreatic Cancer- Future Perspectives and Conclusion
  25. Pancreatic Cancer Analyst Views
  26. Pancreatic Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Idiopathic Membranous Nephropathy Therapeutics Market Size (7MM) was found to be ~USD 130 Million in 2025 and It is projected to grow at a CAGR of 8.2% by 2036, estimates DelveInsight

DelveInsight’s “Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Idiopathic Membranous Nephropathy, historical and forecasted epidemiology, as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Idiopathic Membranous Nephropathy Market Report

  • In January 2026, the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to povetacicept for primary membranous nephropathy, expediting its evaluation process.

  • In November 2025, the FDA granted Fast Track Designation to povetacicept for primary membranous nephropathy, recognizing the significant unmet need in this patient population.

  • According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of Idiopathic Membranous Nephropathy in the 7MM was approximately 89,000 cases.

  • In 2025, the United States held the largest market share for Idiopathic Membranous Nephropathy among the 7MM, accounting for approximately 60% of the total market (~USD 85 million).

  • PLA2R antigen was detected in approximately 23,000 of Idiopathic Membranous Nephropathy patients in the US, with THSD7A present in approximately 800 cases, representing distinct disease subtypes with varying prognosis.

  • Among EU4 and the UK, Germany had the highest prevalent population of Idiopathic Membranous Nephropathy with approximately 6,000 cases, followed by the UK with 5,000 cases in 2025.

  • Rituximab has emerged as the preferred first-line immunosuppressive therapy, achieving durable remission rates of 35-45%, and is expected to maintain significant market presence despite emerging alternatives.

  • The leading Idiopathic Membranous Nephropathy companies such as Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., and others.

  • Promising Idiopathic Membranous Nephropathy Therapies such as SNP-ACTH (1-39), povetacicept, GAZYVA (Obinutuzumab), MOR202 (felzartamab), BRUKINSA (Zanubrutinib), and others.

Stay ahead in the Idiopathic Membranous Nephropathy Therapeutics Market with DelveInsight’s Strategic Report @ Idiopathic Membranous Nephropathy Market Outlook

Idiopathic Membranous Nephropathy Epidemiology Segmentation in the 7MM

  • Patient Burden Assessment

  • Total Diagnosed Prevalent Cases of Idiopathic Membranous Nephropathy

  • Antigen-Specific Cases (PLA2R, THSD7A, NELL-1, Sema3B)

  • Treated Cases of Idiopathic Membranous Nephropathy

  • Disease Severity-based Classification (Low-risk, Moderate-risk, High-risk)

  • Age-specific and Gender-specific Incident Cases

  • Stage-specific Incident Cases of Idiopathic Membranous Nephropathy (Early, Progressive, End-Stage Renal Disease)

  • Comorbidity-Associated Cases (Infections, Autoimmune Disorders, Malignancy-Associated)

  • Response-Based Patient Segmentation (Responders, Partial Responders, Refractory Cases)

Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ Idiopathic Membranous Nephropathy Prevalence

Idiopathic Membranous Nephropathy Pipeline AnalysisSNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

SNP-ACTH (1-39) Gel is a subcutaneous formulation of synthetic porcine ACTH peptide in development as a first-line immunosuppressive therapy for primary membranous nephropathy. A Phase III randomized superiority trial is currently underway comparing SNP-ACTH (1-39) Gel versus rituximab in moderate- to high-risk PMN patients. Preclinical studies and Phase I data have demonstrated safety, tolerability, and potency. The company received FDA Orphan Drug Designation in June 2023 and has secured USD 19 million in total funding to advance this asset, with an estimated annual US cost of USD 105,936 and anticipated launch in 2027.

Povetacicept (ALPN-303): Alphamab Oncology

Povetacicept is a novel B7-2 costimulation molecule inhibitor designed to modulate T-cell activation and reduce pathogenic autoimmune responses in primary membranous nephropathy. In November 2025, the FDA granted Fast Track Designation, and in January 2026, the EMA awarded PRIME designation for accelerated evaluation. Updated data from the ongoing RUBY-3 trial presented at American Society of Nephrology (ASN) Kidney Week 2025 demonstrated significant proteinuria reduction and renal function preservation. Estimated annual US cost is approximately USD 85,000, with anticipated launch expected by 2028-2029.

GAZYVA (Obinutuzumab): Hoffmann-La-Roche

Obinutuzumab is an anti-CD19 monoclonal antibody currently in Phase III development for primary membranous nephropathy (pMN). Real-world retrospective studies have demonstrated strong efficacy, achieving immunological remission rates of 92.0% and clinical remission rates of 83.6%, with significant improvements in proteinuria, serum albumin, and kidney function over median 13-month follow-up. The drug shows efficacy in both rituximab-naïve and rituximab-refractory populations, as well as in anti-PLA2R-negative patients, positioning it as a promising alternative first-line therapy.

MOR202 (Felzartamab): Biogen

MOR202 is a monoclonal antibody targeting CD38 currently in Phase III trials for adult participants with primary membranous nephropathy. Its mechanism provides dual benefits through direct podocyte protection and immune modulation. Preliminary data suggests potential for inducing sustained remission in steroid-resistant and difficult-to-treat PMN populations. Expected regulatory decision targeted for 2029-2030.

BRUKINSA (Zanubrutinib): BeiGene

BRUKINSA is a Bruton’s tyrosine kinase (BTK) inhibitor being evaluated for idiopathic membranous nephropathy management. BTK inhibition reduces pathogenic anti-PLA2R autoantibody production, limits immune complex formation, and dampens inflammatory signaling. Ongoing clinical studies are evaluating its efficacy as both monotherapy and combination therapy with conventional immunosuppression. This represents a paradigm shift toward targeted B-cell directed therapy in IMN treatment.

Idiopathic Membranous Nephropathy Drugs Market Insights

The idiopathic membranous nephropathy market is undergoing significant transformation, driven by advances in biomarker identification and targeted therapeutic development. Circulating autoantibody monitoring, particularly anti-PLA2R and anti-THSD7A assays, has enhanced disease diagnosis, risk stratification, and treatment response monitoring, with declining antibody levels preceding clinical remission in up to 80% of cases.

Emerging therapies are shifting the treatment paradigm toward more targeted immunomodulation. Melanocortin receptor agonists like SNP-ACTH exert direct podocyte-protective effects and demonstrate remission rates of 40-50% in clinical trials. Costimulation modulators such as povetacicept offer novel mechanisms for T-cell regulation, achieving proteinuria remission in 45-60% of treated patients.

Real-world utilization data reveals that immunosuppressive therapy adoption remains suboptimal, with only 35-40% of eligible patients receiving advanced therapies despite available treatment options. Treatment resistance occurs in approximately 30-35% of patients on conventional immunosuppression, driving the need for alternative therapeutic strategies.

Get In-Depth Knowledge on Idiopathic Membranous Nephropathy Market Trends and Forecasts with DelveInsight @ Idiopathic Membranous Nephropathy Treatment Market

Idiopathic Membranous Nephropathy Market Outlook

Idiopathic Membranous Nephropathy (IMN) is a rare but significant glomerular disorder representing the leading cause of nephrotic syndrome in Caucasian adults (~30% of cases), predominantly affecting men aged 30-50 years. The disease is characterized by immune-mediated podocyte injury, resulting in proteinuria, hypoalbuminemia, and nephrotic syndrome.

Current management relies primarily on supportive care with renin-angiotensin system blockade and blood pressure control, followed by immunosuppressive therapies in high-risk patients. Rituximab has emerged as the preferred first-line therapy, achieving 35-45% durable remission rates and sustained immunological remission in rituximab-naïve populations.

The IMN market is experiencing a critical paradigm shift driven by several converging factors. Improved biomarker-based diagnosis has enhanced disease recognition and stratification, enabling earlier intervention and risk-adapted therapy selection.

The projected market growth from USD 130 million in 2025 to USD 1,000 million by 2036 reflects multiple growth drivers: first-in-class therapy approvals, expanded treatment availability for refractory populations, improved disease awareness among clinicians and patients, and increasing diagnostic testing adoption.

Scope of the Idiopathic Membranous Nephropathy Market Report

  • Coverage: 7MM

  • Study Period: 2022-2036

  • Forecast Period: 2026-2036

  • Idiopathic Membranous Nephropathy Companies: Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., Alphamab Oncology, BeiGene, Vertex Pharmaceuticals, and others.

  • Idiopathic Membranous Nephropathy Therapies: SNP-ACTH (1-39), Povetacicept, GAZYVA (Obinutuzumab), MOR202 (Felzartamab), BRUKINSA (Zanubrutinib), and others.

Unlock Strategic Insights with DelveInsight’s Comprehensive Idiopathic Membranous Nephropathy Market Report :https://www.delveinsight.com/infographics/idiopathic-membranous-nephropathy-imn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents

  1. Key Insights

  2. Report Introduction

  3. Executive Summary

  4. Key Events

  5. Epidemiology and Market Forecast Methodology

  6. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance

  7. Disease Background and Overview

  8. Treatment and Management

  9. Epidemiology and Patient Population

  10. Patient Journey

  11. Emerging Drugs

  12. Idiopathic Membranous Nephropathy: Seven Major Market Analysis

  13. Unmet Needs

  14. SWOT Analysis

  15. KOL Views

  16. Market Access and Reimbursement

  17. Appendix

  18. DelveInsight Capabilities

  19. Disclaimer

  20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, the company offers customized research solutions and insights to clients across the globe.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Membranous Nephropathy Therapeutics Market Size (7MM) was found to be ~USD 130 Million in 2025 and It is projected to grow at a CAGR of 8.2% by 2036, estimates DelveInsight